Última actualización 5 de julio de 2026
Key finding
Significant increase in maximum glucose level during hemodialysis (p=0.026).
This study investigated the effects of hemodialysis on plasma glucose and liraglutide levels in patients with diabetes and end-stage renal disease, finding significant increases in maximum glucose and glycemic variability.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
High Risk
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
This study investigated the effects of hemodialysis on plasma glucose and liraglutide levels in patients with diabetes and end-stage renal disease, finding significant increases in maximum glucose and glycemic variability.
Understanding how hemodialysis affects glucose levels is crucial for managing diabetes in patients with end-stage renal disease. The significant increases in maximum glucose and glycemic variability may necessitate adjustments in diabetes treatment protocols to prevent complications.
Non-randomized design may introduce bias. Limited sample size restricts generalizability. Lack of long-term follow-up data.
Published in
Publication details and source links for this paper.
Takeshi O, Miyoko S, Atsuko T, et al. The effect of hemodialysis on the plasma glucose profile and liraglutide level after liraglutide injection was investigated in patients with diabetes and end-stage renal disease (ESRD). PLoS ONE. 2014;9(12):e113468. doi:10.1371/journal.pone.0113468
Maximum glucose levels increased significantly during hemodialysis (p=0.026, 37.8 mg/dL increase).
Standard deviation of glucose levels increased significantly during hemodialysis (p=0.028, 8.4 mg/dL increase).
Mean amplitude of glycemic excursions (MAGE) increased significantly during hemodialysis (p=0.027, 34.4 mg/dL increase).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Liraglutide and AUC during hypoglycemia (<70 mg/dL), Blood glucose, Duration of hypoglycemia, and 8 more.
This study contributes evidence to
Primary intervention
Liraglutide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
11
Evidence pairs
189
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Seguir evidencia
Relación de evidencia
Seguir evidencia
Core evidence
The primary outcomes reported in this study.
Liraglutide → AUC during hypoglycemia (<70 mg/dL)
Liraglutide → AUC during hypoglycemia (<70 mg/dL)
Liraglutide → Duration of hypoglycemia
Liraglutide → Duration of hypoglycemia
Liraglutide → Injection-site adverse reactions
Liraglutide → Injection-site adverse reactions
Liraglutide → Mean amplitude of glycemic excursions (MAGE)
Liraglutide → Mean amplitude of glycemic excursions (MAGE)
Liraglutide → Standard deviation of glucose
Liraglutide → Standard deviation of glucose
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and AUC during hypoglycemia (<70 mg/dL), GLP-1 Receptor Agonists and Fasting Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring AUC during hypoglycemia (<70 mg/dL)
Measures AUC during hypoglycemia (<70 mg/dL) as a key outcome.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
Jump to pre-filtered views in the evidence archive.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Blood glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 8 supporting studies with generally consistent results and a positive effect signal.
Limitations
Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Postprandial and OGTT Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Glucose iAUC (OGTT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 4 supporting studies and existing graph evidence signals.
Limitations
Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for CGM Time in Range.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Time above 13.9 mmol/L
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies and existing graph evidence signals.
Limitations
GLP-1 Receptor Agonists may worsen Glucose Variability or be associated with harm.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Mean amplitude of glycemic excursions (MAGE)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | moderate negative | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Follow the topics this study contributes to.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.